Gross margin held near 74.5% in 2026Q3 and operating margin ranged from 2.4% to 30.3% over the period, suggesting lumpy operating expenses such as the $3.5B R&D spike in 2026Q2 continue to drive earnings volatility.
GSK plc (GSK) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 33.47B | 32.67B | 31.38B | 30.33B | 29.32B | 24.7B | 24.35B | 33.75B | 30.82B | 30.19B | 27.89B | 23.92B | 23.01B | 26.5B | 26.43B | 27.39B | 28.39B | 28.37B | 24.35B | 22.74B | 23.22B | 21.66B | 19.98B | 21.41B | 21.21B | 20.53B | 18.08B | 8.49B | 7.98B | 7.98B | 8.34B |
| Revenue Growth % | 4.06% | 4.11% | 3.46% | 3.42% | 18.74% | 1.4% | -27.85% | 9.52% | 2.1% | 8.24% | 16.58% | 3.99% | -13.2% | 0.28% | -3.49% | -3.54% | 0.08% | 16.49% | 7.1% | -2.06% | 7.21% | 8.4% | -6.71% | 0.95% | 3.3% | 13.58% | 112.94% | 6.35% | 0.04% | -4.33% | -20.49% |
| Cost of Goods Sold | 9.05B | 9.02B | 9.05B | 8.56B | 9.55B | 8.16B | 7.93B | 11.86B | 10.24B | 10.34B | 9.29B | 8.85B | 7.32B | 8.59B | 7.92B | 7.65B | 7.9B | 7.38B | 6.42B | 5.21B | 5.01B | 4.76B | 4.36B | 4.54B | 4.61B | 4.44B | 3.96B | 4.33B | 1.54B | 0 | 0 |
| COGS % of Revenue | - | 27.6% | 28.84% | 28.24% | 32.58% | 33.05% | 32.56% | 35.15% | 33.23% | 34.26% | 33.31% | 37.01% | 31.83% | 32.39% | 29.98% | 27.93% | 27.82% | 26.02% | 26.34% | 22.92% | 21.57% | 22% | 21.82% | 21.19% | 21.73% | 21.62% | 21.91% | 51.05% | 19.35% | - | - |
| Gross Profit | 24.42B | 23.65B | 22.33B | 21.76B | 19.77B | 16.53B | 16.43B | 21.89B | 20.58B | 19.84B | 18.6B | 15.07B | 15.68B | 17.92B | 18.51B | 19.74B | 20.49B | 20.99B | 17.94B | 17.53B | 18.21B | 16.89B | 15.62B | 16.88B | 16.6B | 16.09B | 14.12B | 4.16B | 6.44B | 7.98B | 8.34B |
| Gross Margin % | 72.96% | 72.4% | 71.16% | 71.76% | 67.42% | 66.95% | 67.44% | 64.85% | 66.77% | 65.74% | 66.69% | 62.99% | 68.17% | 67.61% | 70.02% | 72.07% | 72.18% | 73.98% | 73.66% | 77.08% | 78.43% | 78% | 78.18% | 78.81% | 78.27% | 78.38% | 78.09% | 48.95% | 80.65% | 100% | 100% |
| Gross Profit Growth % | - | 5.92% | 2.6% | 10.08% | 19.58% | 0.66% | -24.97% | 6.37% | 3.71% | 6.69% | 23.42% | -3.91% | -12.48% | -3.17% | -6.25% | -3.68% | -2.35% | 17.01% | 2.33% | -3.74% | 7.8% | 8.15% | -7.44% | 1.64% | 3.16% | 14.01% | 239.68% | -35.45% | -19.32% | -4.33% | -20.49% |
| Operating Expenses | 17.59B | 15.31B | 18.31B | 15.02B | 13.34B | 12.18B | 10.45B | 14.93B | 15.1B | 15.76B | 16B | 4.75B | 12.09B | 10.89B | 11.21B | 11.93B | 16.71B | 12.56B | 10.8B | 9.59B | 10.4B | 16.53B | 9.87B | 10.49B | 11.05B | 9.99B | 9.39B | 1.53B | 3.75B | 5.16B | 5.21B |
| OpEx % of Revenue | - | 46.87% | 58.35% | 49.52% | 45.48% | 49.3% | 42.89% | 44.23% | 48.98% | 52.2% | 57.37% | 19.85% | 52.53% | 41.09% | 42.4% | 43.57% | 58.86% | 44.29% | 44.33% | 42.17% | 44.81% | 76.32% | 49.39% | 49% | 52.1% | 48.66% | 51.93% | 18.03% | 47.04% | 64.64% | 62.45% |
| Selling, General & Admin | 9.34B | 9.09B | 11.02B | 9.38B | 8.37B | 7.07B | 7.44B | 11.4B | 9.91B | 9.67B | 9.37B | 9.23B | 8.25B | 8.48B | 8.79B | 8.51B | 12.75B | 9.59B | 7.66B | 6.82B | 7.25B | 7.25B | 7.2B | 7.57B | 0 | 7.47B | 0 | 0 | 0 | 0 | 0 |
| SG&A % of Revenue | - | 27.82% | 35.11% | 30.95% | 28.55% | 28.63% | 30.54% | 33.78% | 32.17% | 32.04% | 33.58% | 38.59% | 35.84% | 31.99% | 33.25% | 31.07% | 44.9% | 33.81% | 31.44% | 30.01% | 31.25% | 33.47% | 36.03% | 35.36% | - | 36.37% | - | - | - | - | - |
| Research & Development | 9.37B | 7.53B | 6.4B | 6.22B | 5.49B | 5.02B | 4.79B | 4.57B | 3.89B | 4.48B | 3.63B | 3.56B | 3.45B | 3.92B | 3.98B | 4.01B | 4.46B | 4.11B | 3.68B | 3.24B | 3.46B | 3.14B | 2.9B | 2.79B | 2.9B | 2.56B | 2.53B | 1.27B | 1.16B | 1.15B | 1.16B |
| R&D % of Revenue | - | 23.04% | 20.4% | 20.52% | 18.71% | 20.32% | 19.68% | 13.53% | 12.63% | 14.83% | 13.01% | 14.88% | 15% | 14.8% | 15.05% | 14.64% | 15.7% | 14.47% | 15.12% | 14.25% | 14.89% | 14.48% | 14.53% | 13.02% | 13.67% | 12.47% | 13.97% | 14.95% | 14.57% | 14.39% | 13.92% |
| Other Operating Expenses | -4M | -1.3B | 891M | -590M | -523M | 87M | -1.78B | -1.04B | 1.29B | 1.61B | 3.01B | -8.04B | 390M | -1.51B | -1.56B | -587M | -493M | -1.14B | -541M | -475M | -307.78M | 6.14B | -235.13M | 133.28M | 8.15B | -37.16M | 6.86B | 262M | 2.59B | 4.01B | 4.05B |
| Operating Income | 6.83B | 8.34B | 4.02B | 6.75B | 6.43B | 4.36B | 5.98B | 6.96B | 5.48B | 4.09B | 2.6B | 10.32B | 3.6B | 7.03B | 7.3B | 7.81B | 3.78B | 8.43B | 7.14B | 7.94B | 7.19B | 6.86B | 5.26B | 6.38B | 5.55B | 6.1B | 4.73B | 2.63B | 2.68B | 2.82B | 3.13B |
| Operating Margin % | 20.4% | 25.52% | 12.82% | 22.24% | 21.94% | 17.64% | 24.55% | 20.62% | 17.79% | 13.54% | 9.32% | 43.15% | 15.64% | 26.52% | 27.62% | 28.51% | 13.32% | 29.7% | 29.32% | 34.91% | 30.95% | 31.7% | 26.33% | 29.81% | 26.17% | 29.72% | 26.16% | 30.92% | 33.61% | 35.36% | 37.55% |
| Operating Income Growth % | - | 107.36% | -40.39% | 4.85% | 47.65% | -27.13% | -14.11% | 26.96% | 34.16% | 57.31% | -74.83% | 186.96% | -48.82% | -3.73% | -6.49% | 106.37% | -55.1% | 17.98% | -10.05% | 10.48% | 4.68% | 30.52% | -17.61% | 15% | -9.05% | 29.06% | 80.15% | -2.16% | -4.93% | -9.9% | 31.49% |
| EBITDA | 9.03B | 10.65B | 6.57B | 9.04B | 8.58B | 6.48B | 8.03B | 9.29B | 7.34B | 6.01B | 4.37B | 11.95B | 5.08B | 8.44B | 8.74B | 9.23B | 5.46B | 9.99B | 8.37B | 8.96B | 8.14B | 7.77B | 6.12B | 7.24B | 6.38B | 6.92B | 5.46B | 3.05B | 3.04B | 3.19B | 3.54B |
| EBITDA Margin % | 26.99% | 32.61% | 20.95% | 29.8% | 29.26% | 26.24% | 32.97% | 27.54% | 23.81% | 19.91% | 15.68% | 49.96% | 22.09% | 31.85% | 33.09% | 33.7% | 19.24% | 35.21% | 34.38% | 39.41% | 35.08% | 35.87% | 30.63% | 33.82% | 30.05% | 33.68% | 30.22% | 35.96% | 38.09% | 40.04% | 42.46% |
| EBITDA Growth % | -15.25% | 62.08% | -27.29% | 5.35% | 32.43% | -19.3% | -13.62% | 26.65% | 22.13% | 37.44% | -63.42% | 135.23% | -39.81% | -3.46% | -5.25% | 68.99% | -45.31% | 19.29% | -6.58% | 10.04% | 4.83% | 26.97% | -15.52% | 13.61% | -7.82% | 26.57% | 78.97% | 0.39% | -4.82% | -9.8% | 21.51% |
| D&A (Non-Cash Add-back) | 2.21B | 2.31B | 2.55B | 2.29B | 2.15B | 2.12B | 2.05B | 2.33B | 1.86B | 1.92B | 1.77B | 1.63B | 1.48B | 1.41B | 1.45B | 1.42B | 1.68B | 1.56B | 1.23B | 1.02B | 958.04M | 903.7M | 858.68M | 859.04M | 824M | 812.8M | 735M | 428M | 358M | 373M | 410M |
| EBIT | 6.52B | 8.09B | 4.12B | 6.79B | 6.45B | 4.36B | 6.02B | 7.1B | 5.49B | 4.26B | 2.66B | 11.26B | 3.67B | 7.39B | 7.36B | 8.45B | 3.94B | 8.67B | 7.5B | 8.2B | 7.81B | 363.81M | 5.75B | 6.38B | 5.71B | 6.1B | 6.35B | 2.78B | 2.87B | 2.91B | 3.24B |
| Net Interest Income | -631.5M | -631M | -590.19M | -735M | -791.26M | -755M | -852M | -810.89M | -665.8M | -667M | -662M | -650M | -628.53M | -705M | -662.96M | -654.46M | -687.53M | -713M | -530M | -59.35M | -65M | -194M | -186M | 0 | -133M | 0 | -159M | -92M | -91M | -123M | -187M |
| Interest Income | 108.77M | 56M | 67.39M | 40M | 64.27M | 28M | 44M | 98M | 77.83M | 65M | 72M | 104M | 67.67M | 61M | 72.02M | 87.88M | 77.83M | 70M | 313M | 255.5M | 287M | 257M | 176M | 0 | 73M | 0 | 158M | 114M | 111M | 104M | 89M |
| Interest Expense | 740.28M | 687M | 657.58M | 775M | 855.53M | 784M | 892M | 912M | 743.64M | 734M | 736M | 757M | 696.2M | 767M | 734.97M | 742.34M | 765.36M | 783M | 843M | 314.85M | 352M | 451M | 362M | 161M | 206M | 1.15B | 317M | 206M | 202M | 227M | 276M |
| Other Income/Expense | -1.46B | -937M | -544M | -681M | -805M | -758M | -809M | -740M | -683M | -562M | -659M | 204M | -629M | -381M | -700M | -109M | -626M | -534M | -482M | -402.39M | 285.49M | 234.1M | 188.63M | -62.72M | -45M | -17.89M | 1.3B | -50M | -12M | -136M | -168M |
| Pretax Income | 5.37B | 7.4B | 3.48B | 6.06B | 5.63B | 3.6B | 5.17B | 6.22B | 4.8B | 3.52B | 1.94B | 10.53B | 2.97B | 6.65B | 6.6B | 7.7B | 3.16B | 7.89B | 6.66B | 7.54B | 7.47B | 7.1B | 5.45B | 6.32B | 5.51B | 6.09B | 6.03B | 2.58B | 2.67B | 2.69B | 2.96B |
| Pretax Margin % | 16.04% | 22.66% | 11.08% | 19.99% | 19.19% | 14.57% | 21.23% | 18.43% | 15.57% | 11.68% | 6.95% | 44% | 12.9% | 25.08% | 24.97% | 28.11% | 11.12% | 27.82% | 27.34% | 33.14% | 32.18% | 32.78% | 27.27% | 29.52% | 25.96% | 29.64% | 33.35% | 30.33% | 33.46% | 33.66% | 35.54% |
| Income Tax | 559.17M | 1.11B | 526M | 756M | 707M | 83M | 67M | 953M | 754M | 1.36B | 877M | 2.15B | 137M | 1.02B | 1.92B | 2.24B | 1.3B | 2.22B | 1.95B | 2.15B | 2.2B | 2.02B | 1.67B | 1.74B | 1.46B | 1.65B | 1.75B | 746M | 815M | 819M | 933M |
| Effective Tax Rate % | 10.42% | 15.02% | 15.13% | 12.47% | 12.56% | 2.31% | 1.3% | 15.32% | 15.71% | 38.47% | 45.23% | 20.46% | 4.62% | 15.33% | 29.12% | 29.1% | 41.31% | 28.16% | 29.24% | 28.59% | 29.5% | 28.46% | 30.72% | 27.47% | 26.53% | 27.12% | 28.98% | 28.97% | 30.51% | 30.49% | 31.48% |
| Net Income | 4.34B | 5.72B | 2.58B | 4.93B | 14.96B | 4.38B | 5.75B | 4.64B | 3.62B | 1.53B | 912M | 8.42B | 2.76B | 5.44B | 4.5B | 5.26B | 1.63B | 5.53B | 4.6B | 5.22B | 5.39B | 4.69B | 3.91B | 4.48B | 3.94B | 3.1B | 4.16B | 1.81B | 1.84B | 1.85B | 2B |
| Net Margin % | 12.96% | 17.5% | 8.21% | 16.25% | 51% | 17.76% | 23.61% | 13.76% | 11.76% | 5.08% | 3.27% | 35.2% | 11.98% | 20.51% | 17.02% | 19.21% | 5.76% | 19.5% | 18.9% | 22.95% | 23.2% | 21.65% | 19.55% | 20.91% | 18.55% | 15.1% | 23.02% | 21.33% | 23% | 23.18% | 23.94% |
| Net Income Growth % | -21.03% | 121.98% | -47.75% | -67.05% | 241.07% | -23.73% | 23.77% | 28.21% | 136.49% | 67.98% | -89.17% | 205.59% | -49.3% | 20.83% | -14.48% | 221.97% | -70.46% | 20.19% | -11.83% | -3.12% | 14.93% | 20.01% | -12.78% | 13.81% | 26.94% | -25.52% | 129.82% | -1.36% | -0.76% | -7.36% | 36.97% |
| Net Income (Continuing) | 4.81B | 6.29B | 2.95B | 5.31B | 4.92B | 3.52B | 5.1B | 5.27B | 4.05B | 2.17B | 1.06B | 8.37B | 2.83B | 5.63B | 4.68B | 5.46B | 1.85B | 5.67B | 4.71B | 5.34B | 5.39B | 4.69B | 3.77B | 4.48B | 4.04B | 4.43B | 4.28B | 1.83B | 1.86B | 1.87B | 2.03B |
| Discontinued Operations | 0 | 0 | 0 | 0 | 10.7B | 1.58B | 1.28B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -394.63M | -420.26M | -585M | -703.69M | -502M | 8.52B | 8.5B | 9.21B | -688M | 3.56B | 3.84B | 3.76B | 673M | 815M | 937M | 795M | 858M | 737M | 387M | 307M | 262M | 259M | 213M | 744.24M | 807M | 863.73M | 1.24B | 51M | 66M | 47M | 42M |
| EPS (Diluted) | 2.13 | 2.78 | 1.24 | 2.40 | 7.32 | 2.70 | 2.86 | 2.32 | 1.82 | 0.78 | 0.46 | 4.30 | 1.42 | 2.76 | 2.26 | 2.58 | 0.80 | 2.70 | 2.20 | 2.34 | 2.36 | 2.04 | 1.70 | 1.92 | 1.66 | 1.26 | 1.68 | 1.24 | 1.26 | 1.28 | 1.42 |
| EPS Growth % | -19.17% | 124.19% | -48.33% | -67.21% | 171.11% | -5.59% | 23.28% | 27.47% | 133.33% | 69.57% | -89.3% | 202.82% | -48.55% | 22.12% | -12.4% | 222.5% | -70.37% | 22.73% | -5.98% | -0.85% | 15.69% | 20% | -11.46% | 15.66% | 31.75% | -25% | 35.48% | -1.59% | -1.56% | -9.86% | 26.79% |
| EPS (Basic) | - | 2.82 | 1.26 | 2.44 | 7.44 | 2.74 | 2.88 | 2.34 | 1.84 | 0.78 | 0.48 | 4.36 | 1.44 | 2.82 | 2.30 | 2.62 | 0.80 | 2.72 | 2.22 | 2.36 | 2.38 | 2.06 | 1.70 | 1.94 | 1.66 | 1.26 | 1.70 | 1.26 | 1.28 | 1.30 | 1.42 |
| Diluted Shares Outstanding | 2.04B | 2.06B | 2.07B | 2.06B | 2.04B | 1.62B | 2.02B | 2.01B | 1.99B | 1.98B | 1.96B | 1.96B | 1.95B | 1.97B | 2B | 2.04B | 2.05B | 2.04B | 2.09B | 2.23B | 2.28B | 2.29B | 2.29B | 2.32B | 2.37B | 2.45B | 2.45B | 2.91B | 2.91B | 2.88B | 2.82B |
| Basic Shares Outstanding | 2B | 2.03B | 2.04B | 2.03B | 2.01B | 1.6B | 1.99B | 1.98B | 1.97B | 1.95B | 1.94B | 1.93B | 1.92B | 1.93B | 1.96B | 2.01B | 2.03B | 2.03B | 2.08B | 2.21B | 2.26B | 2.28B | 2.29B | 2.31B | 2.36B | 2.43B | 2.43B | 2.9B | 2.88B | 2.85B | 2.82B |
| Dividend Payout Ratio | - | 43.87% | 94.91% | 56.68% | 28.55% | 91.2% | 69.18% | 85.1% | 108.39% | 254.96% | 531.8% | 46% | 139.44% | 67.7% | 84.77% | 64.74% | 196.14% | 54.29% | 63.65% | 53.51% | 48.22% | 50.99% | 63.36% | 52.03% | 59.14% | 75.18% | - | - | - | - | - |
Quick answers to the most common questions about buying GSK stock.
For fiscal year 2025, GSK plc (GSK) reported total revenue of $32.67B. This represents a 291.6% increase compared to $8.34B in 1996.
GSK plc (GSK) is profitable, generating $5.72B in net income for the fiscal year ending 2025 with a net profit margin of 17.5%.
GSK plc (GSK) reported an operating income of $8.34B, resulting in an operating profit margin of 25.5%. This margin reflects the operational efficiency of the business before interest and taxes.
GSK plc (GSK) generated $23.65B in gross profit for the year, representing a gross profit margin of 72.4%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Legacy litigation and HIV generic exposure
Top-Line Growth Decelerating Toward Low Single Digits
Based on reported quarterly figures, GSK's revenue growth has moderated from roughly 9.8% in 2024Q2 to a range of 1.5% to 6.7% across recent quarters, indicating growth that is positive but no longer accelerating.
The reported series shows volatility rather than a clean trend, with the highest growth prints coming from the most recent 2026Q3 quarter at 3.2% and 2025Q3 at 6.7%. This pattern suggests that vaccine timing and government procurement cycles may be driving much of the quarter-to-quarter variation rather than a durable step-change in demand. Investors should monitor whether the Arexvy and Shingrix franchises can sustain mid-single-digit growth once legacy respiratory and HIV volumes face pricing pressure.
High Gross Margins Anchored by Specialty Mix
GSK's gross margin has held in a 68.5% to 75.4% band across the ten reported quarters, with the 74.5% print in 2026Q3 suggesting the specialty and vaccine mix continues to carry the portfolio.
The margin profile sits at the upper end of the large-cap pharma peer set, which indicates that pricing power in HIV and differentiated vaccines is offsetting the lower-margin legacy respiratory and antibiotic volumes. The dip toward 68.5% in 2024Q4 appears to align with seasonal procurement mix rather than a structural shift, though this remains an inference from the data provided. Sustained margins near 75% would depend on continued HIV franchise pricing and avoiding a faster-than-expected erosion from generic entrants.
Operating Margin Swings Reflect Lumpy Opex
Reported operating margins ranged from 2.4% to 30.3% over the period, and the gap between gross and operating margin widened sharply in 2024Q3 and 2026Q2, according to the reported income statement figures.
Operating income appears far more sensitive to SG&A and R&D timing than to gross profit, as the 2024Q3 SG&A spike to $3.8B collapsed operating margin despite stable gross profit of $5.6B. This suggests that the cost base carries substantial discretionary or lumpy components, making operating leverage unreliable on a quarterly basis. The recovery to 28.9% in 2026Q3 indicates the business can convert gross profit efficiently when opex normalizes.
Net Income Volatility Warrants Adjusted Earnings Scrutiny
Net income has swung from a loss of $58.0M in 2024Q3 to $2.0B in 2025Q3, and EPS growth figures ranging from -103.9% to 56.0% suggest headline earnings are heavily affected by non-recurring items.
The magnitude of these swings relative to revenue indicates that legal provisions, restructuring charges, and portfolio-related adjustments may be materially influencing reported results, consistent with the known gap between IFRS and adjusted figures. Stock-based compensation is reported as zero across the period, so its impact on quality cannot be assessed from this data. Investors should reconcile reported EPS against adjusted EPS before drawing conclusions about underlying earnings power.
Legacy Litigation and Opex Could Compress Margins
Bears would point to the 2024Q3 operating margin collapse to 2.4% and the 2026Q2 R&D spike to $3.5B as evidence that unpredictable legal and development costs could erode the margin base.
A bearish reading would argue that recurring R&D intensity and unprovisioned Zantac-related exposure may keep operating income volatile even when gross margins remain strong. If HIV generic competition accelerates, the high gross margin buffer could narrow faster than new franchises like RSV can offset. This interpretation rests on the reported figures and warrants further investigation into provisioning disclosures.